Panacea Biotec and Refana collaborate for Covid-19 vaccine

Global development, manufacturing and distribution of the Candidate Covid-19 vaccine

Photo - Arek Socha from Pixabay

Panacea Biotec is advancing its response to address the unprecedented challenges of Covid-19 by collaborating with Refana USA to make the Covid-19 vaccine widely accessible around the world in an equitable manner through a Joint Venture company to be based in Ireland.

The collaboration aims to bring to patients a whole inactivated virus-based vaccine for Covid-19. Under the collaboration, Panacea Biotec will be responsible for product development and commercial manufacturing, with the Joint Venture undertaking clinical development and regulatory submissions across the world. Both Panacea and Refana will undertake sales and distribution of the vaccine in their respective territories.

Rajesh Jain, managing director, Panacea Biotec, said, “The World needs a safe, effective, and scalable vaccine in a cGMP compliant manufacturing facility with sizeable capacity and capability to cater to global demand. Our collaboration with Refana aims to manufacture over 500 million doses of our Covid-19 candidate vaccine, with over 40 million doses expected to be available for delivery early next year. Whole inactivated viral vaccines have a higher probability of being safe and efficient, given their long history and a better understanding of their mechanism of action, which has been elucidated over many decades. This vaccine has the potential to become the Vaccine of Choice for the global fight against Covid-19.”

Phillip Schwartz, chief scientific and medical advisor of Refana, stated “Refana and its international network of scientific researchers and practitioners are dedicated to finding practical solutions to complex and urgent global medical problems. We are grateful for the input from dozens of medical scientists and epidemiologists in more than a dozen countries in this unprecedented worldwide collaboration to end Covid-19. Our partnership with Panacea Biotec brings this dream to a practical realization with the ability to manufacture 500 million Covid-19 vaccines over 12 months. Utilizing proven models of viral pathogenesis and parallel conduct of multiple pre-clinical and clinical studies, Refana believes it can significantly accelerate the vaccine development and approval process for its tried and true whole inactivated viral vaccine approach. We are very excited to combine this approach with Panacea Biotec’s world-class technology, development, and production capabilities.”


Please enter your comment!
Please enter your name here